control rat pulmonary artery smooth muscle cells rpasmcs  (Cell Applications Inc)

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Negative Control, CCK-8 Assay, Staining, Transfection, Expressing, Control, Cell Counting, Small Interfering RNA

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , hnRNPA1, IQGAP1, PKM2 and β-actin protein expression in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control siRNA or hnRNPA1 siRNA. B–D , Ratio of hnRNPA1/β-actin (B) PKM2/β-actin (C) and IQGAP1/β-actin (D) in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control or hnRNPA1 siRNAs. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; IQGAP1, IQ motif containing GTPase activating protein 1; PKM2, pyruvate kinase M 2; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Expressing, Negative Control, Control, Small Interfering RNA

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , hnRNPA1 and β-actin protein expression in hypoxia-treated rPASMCs treated with tetracaine. B , Ratio of hnRNPA1/β-actin in hypoxia-treated rPASMCs treated with tetracaine. C , Proliferative capacity of hypoxia-treated rPASMCs treated with tetracaine, measured via the CCK-8 assay. D , rPSAMCs stained with Hoechst dye 72 h after tetracaine treatment. E , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after tetracaine treatment. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 3 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Expressing, CCK-8 Assay, Staining, Cell Counting

Journal: The American Journal of Pathology

Article Title: Exploratory Study of Prognostic Plasma Biomarkers in Patients with Pulmonary Arterial Hypertension

doi: 10.1016/j.ajpath.2025.04.018

Figure Lengend Snippet: Incremental predicted performance of identified biomarkers and expression in animal models. A: Performance of the logistic regression models with 2015 European Respiratory Society (ERS)/European Society of Cardiology (ESC) risk score, REVEAL 2.0 risk score, and the refined four-strata risk assessment method in patients with PAH for death and lung transplantation. Graph of C-statistics with 95% CI for each biomarker and their combinations. C-statistics were compared using the DeLong test with each reference. B: Heat map showing RNA-sequencing expression data of the indicated genes [in transcripts per million (TPM)] obtained from the Genotype-Tissue Expression (GTEx version 8) database ( https://gtexportal.org/home , last accessed August 13, 2024) in lung, heart, artery, kidney, liver, and adipose tissue. C: Western blot analyses and corresponding quantifications of WFDC2 (HE4) in right ventricles and dissected pulmonary arteries (PAs) from monocrotaline (MCT)–injected and Sugen/hypoxia (Su/Hx)–exposed rats. D: Western blot analyses and corresponding quantifications of WFDC2 (HE4) in kidney from MCT-injected and Su/Hx-exposed rats. E: Wfdc2 mRNA expression in right ventricle (RV), lung, and kidney of control (CTRL) and MCT-injected or Su/Hx-exposed rats. F: Representative fluorescent images of 5-ethynyl-2′-deoxyuridine (EdU)–labeled control pulmonary artery smooth muscle cells (PASMCs) and control cardiac fibroblasts (CFs) exposed or not to recombinant human WFDC2 (rhWFDC2; 40 nmol/L) for 24 and 48 hours, respectively. Ar row s indicate EdU-positive cells. The corresponding quantifications are shown. Scatter dot plots show individual values. Protein expression was normalized to amido black (AB). Statistical analyses were performed using t -test. Data are given as means ± SEM ( A and E ). n = 6 to 16 ( E ); n = 3 control PASMCs ( F ); n = 4 control CFs ( F ). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Scale bars = 100 μm ( F ). Veh, vehicle.

Article Snippet: Control pulmonary artery smooth muscle cells (PASMCs; n = 5 cell lines) were either purchased from Cell Applications (San Diego, CA) or isolated from patients without PAH.

Techniques: Expressing, Transplantation Assay, Biomarker Discovery, RNA Sequencing, Western Blot, Injection, Control, Labeling, Recombinant